Bonjour, new guests from small-town India
Puneet Dhawan of Accor is brimming with ideas on ways to revive the hospitality sector
Medication for high blood pressure may improve Covid-19 survival rates, and reduce the severity of novel coronavirus infection, particularly in patients with hypertension, according to a study.
Researchers from the University of East Anglia (UEA) in the UK studied 28,000 patients taking antihypertensives -- a class of drugs that are used to treat hypertension or high blood pressure.
The study, published in the journal Current Atherosclerosis Reports, found that the risk of severe Covid-19 illness and death was reduced for patients with high blood pressure who were taking Angiotensin-Converting Enzyme inhibitors (ACEi) or Angiotensin Receptor Blockers (ARB).
“We know that patients with cardiovascular diseases are at particular risk of severe Covid-19 infection,” said lead researcher Vassilios Vassiliou, from UEA’s Norwich Medical School.
“But at the start of the pandemic, there was concern that specific medications for high blood pressure could be linked with worse outcomes for Covid-19 patients,” Vassiliou said.
The researchers, including those from Norfolk and Norwich University Hospital, analysed what the impact of these medications is for people with Covid-19.
They studied the outcomes for patients taking antihypertensives, looking particularly at what is called ‘critical’ outcomes such as being admitted to intensive care or being put on a ventilator, and death.
The team analysed data from 19 studies related to Covid-19 and ACEi and ARB medications. The researchers noted that their meta-analysis involved more than 28,000 patients and is the largest and most detailed such study to date.
They compared data from Covid-19 patients who were taking ACEi or ARB medications with those who were not -- focusing on whether they experienced ‘critical’ events and death.
“We found that a third of Covid-19 patients with high blood pressure and a quarter of patients overall were taking an ACEi/ARBs. This is likely due to the increasing risk of infection in patients with co-morbidities such as cardiovascular diseases, hypertension and diabetes, said Vassiliou.
“But the really important thing that we showed was that there is no evidence that these medications might increase the severity of Covid-19 or risk of death, he said.
On the contrary, the researchers found that there was a significantly lower risk of death and critical outcomes, so they might in fact have a protective role -- particularly in patients with hypertension.
Covid-19 patients with high blood pressure who were taking ACEi/ARB medications were 0.67 times less likely to have a critical or fatal outcome than those not taking these medications, according to the study.
“Our research provides substantial evidence to recommend continued use of these medications if the patients were taking them already, said Vassiliou.
“However, we are not able to address whether starting such tablets acutely in patients with Covid-19 might improve their prognosis, as the mechanism of action might be different,” he added.
Puneet Dhawan of Accor is brimming with ideas on ways to revive the hospitality sector
Citroen’s first vehicle sports a novel design and European interiors. It is also meant to be as comfortable as ...
The pandemic is only the tip of the iceberg that the country’s cash-poor airlines — both regional and national ...
The government is yet to specify the framework of its recently announced old vehicle scrappage policy
Here is a checklist that equips you to discern the market nuances
Sensex, Nifty 50 have witnessed sharp decline
The fund has consistently outperformed S&P BSE 100 TRI over one, three and five years
Returns are superior to immediate annuity plans, but SCSS can secure better rates for new investors sooner if ...
With the public looking beyond mainstream media for reports from the ground, independent digital platforms are ...
The country hasn’t had a quiet moment since the military seized power on February 1
The Tatmadaw sees itself as an embodiment of the nationalist soul of Myanmar. But their brand of nationalism ...
While Supreme Court has cleared the way for women seeking longer tenures and senior roles in the Indian Army, ...
Its name is the starting point of a brand’s journey and can make a big difference in the success sweepstakes
Sober spirits are the in thing
A peek into where ad spends went last year and where they are headed tomorrow
Can Swiggy Instamart disrupt the ecommerce groceries space, currently ruled by the Amazons and Big Baskets? ...
Three years after its inception, compliance with GST procedures remains a headache for exporters, job workers ...
Corporate social responsibility (CSR) initiatives of companies are altering the prospects for wooden toys of ...
Aequs Aerospace to create space for large-scale manufacture of toys at Koppal
And it has every reason to smile. Covid-19 has triggered a consumer shift towards branded products as ...
Please Email the Editor